Cytokinetics, Incorporated, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel muscle activators and muscle inhibitors as potential treatments for debilitating diseases in the United States. The company markets MYQORZO, a novel, oral, and small molecule cardiac myosin inhibitor for the treatment of symptomatic oHCM. It also develops Aficamten, a novel, oral, and small molecule cardiac myosin inhibitor for the treatment of HCM; and omecamtiv mecarbil, a potential treatment across the continuum of care in heart failure with severely reduced ejection fraction. In addition, the company is involved in developing and Ulacamten, a novel, selective, oral, and small molecule cardiac myosin inhibitor designed to reduce the hypercontractility associated with heart failure with preserved ejection fraction in Phase 1 clinical trials; and CK-089, a fast skeletal muscle troponin activator in Phase 1 clinical trials. Cytokinetics, Incorporated was incorporated in 1997 and is headquartered in South San Francisco, California.
| Business Activity | PASS |
| Debt Ratio | N/A |
| Cash Ratio | N/A |
| Receivables Ratio | N/A |
| Revenue Ratio (0.00%) | PASS |
| Overall | PASS |
$10.2B
-11.55
0.380
20
$105.8M
$1.4B
1.59
5.03
0.2%
673
| Shares | Cost | Profit to Target | R:R |
|---|---|---|---|
| To Consensus ($104.70, 20 analysts) | |||
| 10 | $771.50 | +$275.50 (36%) | 2.4R |
| 50 | $3,857.50 | +$1,377.50 (36%) | 2.4R |
| 100 | $7,715.00 | +$2,755.00 (36%) | 2.4R |
- Elevated short interest (5.03 days to cover)
A single score combining all analytical layers below. A is strongest, D is weakest.
How much could this ticker lose on a bad day? These metrics measure worst-case scenarios from historical data.
Based on 10,000 simulated price paths, here is the probability of where this ticker could be in 30, 60, and 90 days.
What direction is this ticker actually moving, filtered through noise? Is it speeding up or slowing down?
Classic chart signals that institutional traders monitor. Golden Cross is bullish, Death Cross is bearish.
Is this company financially sound? The Z-Score measures bankruptcy risk. The F-Score measures fundamental strength.
These tickers tend to move together (positive) or in opposite directions (negative). Useful for portfolio diversification.
| Ticker | Correlation |
|---|---|
| MLYS | 0.447 |
| IDYA | 0.439 |
| HQH | 0.414 |
| ARKG | 0.394 |
| DNLI | 0.388 |
| Ticker | Correlation |
|---|---|
| ESTERAD.BH | -0.156 |
| FME.DE | -0.139 |
| CBOE | -0.137 |
| BNH.BH | -0.131 |
| 9557.SR | -0.124 |
Does this ticker have consistent patterns on certain days or months? Historical tendencies, not guarantees.
How does this ticker's recent performance compare to the entire universe? Ranked across 1, 3, 6, and 12-month returns.